Status:

RECRUITING

A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

Lead Sponsor:

Chinese PLA General Hospital

Collaborating Sponsors:

First Affiliated Hospital of Harbin Medical University

Yantai Yuhuangding Hospital

Conditions:

Acute Myeloid Leukemia

First Line Therapy

Eligibility:

All Genders

14-75 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to compare the efficacy and safety of venetoclax combined with the CACAG regimen with the traditional "3+7" regimen in the treatment of newly diagnosed intermediate- or hi...

Detailed Description

Despite the availability of hematopoietic stem cell transplantation and the emergence of many new therapeutic drugs, the prognosis of newly diagnosed acute myeloid leukemia is still poor.Over the past...

Eligibility Criteria

Inclusion

  • Age 14 to 75 years (no gender limitation) Newly diagnosed with intermediate- or high-risk AML (excluding M3) Liver function: ALT and AST ≤ 2.5 times upper limit of normal; bilirubin ≤ 2 times upper limit of normal Renal function: creatinine ≤ upper limit of normal No uncontrolled infections, organ dysfunction, or severe mental illness ECOG performance status score of 0-2 and predicted survival ≥ 4 months No severe allergic constitution

Exclusion

  • Allergy or contraindication to the study drug Pregnant or breastfeeding female patients Known history of alcohol or drug addiction (due to potential non-compliance) Mental illness or conditions preventing protocol compliance Less than 6 weeks after major organ surgery Liver function: ALT and AST \> 2.5 times upper limit of normal; bilirubin \> 2 times upper limit of normal Renal function: creatinine \> upper limit of normal Deemed unsuitable for the clinical trial (poor compliance, substance abuse, etc.)
  • \-

Key Trial Info

Start Date :

April 18 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 18 2026

Estimated Enrollment :

160 Patients enrolled

Trial Details

Trial ID

NCT06928376

Start Date

April 18 2024

End Date

October 18 2026

Last Update

April 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Chinese PLA General Hospital

Beijing, Beijing Municipality, China, 100853